Martin M, Lopez-Tarruella S. Emerging therapeutic options for HER2-positive breast Cancer. Am Soc Clin Oncol Educ Book/ASCO Am Soc Clin Oncol Meet. 2016;35:e64–70.
Article
Google Scholar
Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–34.
Article
CAS
Google Scholar
Araki K, Fukada I, Yanagi H, Kobayashi K, Shibayama T, Horii R, Takahashi S, Akiyama F, Ohno S, Ito Y. First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer. Breast. 2017;35:78–84.
Article
Google Scholar
Muntasell A, Cabo M, Servitja S, Tusquets I, Martinez-Garcia M, Rovira A, Rojo F, Albanell J, Lopez-Botet M. Interplay between natural killer cells and anti-HER2 antibodies: perspectives for breast Cancer immunotherapy. Front Immunol. 2017;8:1544.
Article
Google Scholar
Lee SC, Srivastava RM, Lopez-Albaitero A, Ferrone S, Ferris RL. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res. 2011;50(2–3):248–54.
Article
CAS
Google Scholar
Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 2017;18(1):52–62.
Article
CAS
Google Scholar
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70.
Article
CAS
Google Scholar
Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.
Article
Google Scholar
Slaney CY, Kershaw MH, Darcy PK. Trafficking of T cells into tumors. Cancer Res. 2014;74(24):7168–74.
Article
CAS
Google Scholar
Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016;22(4):433–8.
Article
CAS
Google Scholar
Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69(13):5383–91.
Article
CAS
Google Scholar
Koh CH, Bhoo-Pathy N, Ng KL, Jabir RS, Tan GH, See MH, Jamaris S, Taib NA. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer. 2015;113(1):150–8.
Article
CAS
Google Scholar
Asano Y, Kashiwagi S, Onoda N, Noda S, Kawajiri H, Takashima T, Ohsawa M, Kitagawa S, Hirakawa K. Predictive value of neutrophil/lymphocyte ratio for efficacy of preoperative chemotherapy in triple-negative breast Cancer. Ann Surg Oncol. 2016;23(4):1104–10.
Article
Google Scholar
Xu J, Ni C, Ma C, Zhang L, Jing X, Li C, Liu Y, Qu X. Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy. Clin Transl Oncol. 2017;19(8):989–96.
Article
CAS
Google Scholar
Chen Y, Chen K, Xiao X, Nie Y, Qu S, Gong C, Su F, Song E. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. BMC Cancer. 2016;16:320.
Article
Google Scholar
Rodríguez DM, Guerrero ME, Maldonado BM, Vollbracht C, Herrera SA. Total lymphocyte count in cancer patients with lymphopenia treated with intravenous vitamin C: Results of an observational study. Translat Med Commun. 2017;2:3.
Efremova M, Finotello F, Rieder D, Trajanoski Z. Neoantigens generated by individual mutations and their role in Cancer immunity and immunotherapy. Front Immunol. 2017;8:1679.
Article
Google Scholar
Kroemer G, Senovilla L, Galluzzi L, Andre F, Zitvogel L. Natural and therapy-induced immunosurveillance in breast cancer. Nat Med. 2015;21(10):1128–38.
Article
CAS
Google Scholar
Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009;69(24):9330–6.
Article
CAS
Google Scholar
Watanabe T, Hida AI, Inoue N, Imamura M, Fujimoto Y, Akazawa K, Hirota S, Miyoshi Y. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers. Breast Cancer Res Treat. 2018;168(1):135–45.
Article
CAS
Google Scholar
Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690–714.
Article
CAS
Google Scholar
Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010;10(3):194–204.
Article
CAS
Google Scholar